Cipla Ltd Company Summary

Cipla Ltd is one of India’s oldest and most trusted pharmaceutical companies, advancing affordable healthcare and developing a large global portfolio of medicines, APIs and complex therapies.

Company Overview

Cipla is a global pharmaceutical company with a strong presence. Based in Mumbai, it runs over 40 modern manufacturing facilities across India and other markets.

It has grown into a trusted healthcare brand known for its strength in respiratory, urology, cardiology, anti-retroviral treatments, and complex generics. Cipla supplies medicines and APIs to hospitals, government programmes, retail customers, and global generic partners through an integrated research and manufacturing network.

Founding & Evolution

• Founded: Incorporated in 1935 by Khwaja Abdul Hamied, who contributed all his patents and proprietary drug formulas to the company royalty-free, shaping Cipla’s purpose-driven approach to healthcare.
• Listed Year: Registered as a public limited company on 17 August 1935. Listed on NSE on 8 February 1995.
• Leadership: Mr Umang Vohra serves as Managing Director and Global Chief Executive Officer.
• Strategic Acquisitions & Alliances: Acquisition of Cipla Medpro South Africa Ltd (2013), InvaGen Pharmaceuticals Inc. and Exelan Pharmaceuticals Inc. in the US (2016), Anmarate (Pty) Ltd. in South Africa (2018).

Scale and Presence

Cipla manages a broad and globally dispersed presence across regulated and emerging markets, supported by large-scale manufacturing and R&D infrastructure.

• Manufacturing Footprint: Operates 40+ manufacturing sites across India, the USA, China, South Africa and additional regions. These include formulation plants, API facilities and specialised research centres.
• Employees: Supported by a large workforce across global operations, including more than 55 subsidiary entities as of 2021.
• International Operations: Strong presence in South Africa, North America and emerging markets. About 22% of its revenue comes from North America (as of September 2023), and India contributes slightly less than 50%.
• Branches/Sites: Functions through manufacturing units, R&D centres, distribution hubs and subsidiary networks rather than traditional branch offices.
• Customer Base: Serves hospitals, government bodies, healthcare programmes, retail consumers, pharmacies and global pharmaceutical manufacturers through formulation supply and API partnerships.

Business Segments

Cipla positions itself as a diversified healthcare company with a wide portfolio spanning formulations, APIs and consumer health, supported by R&D and strong regulatory capabilities.

Key operating clusters include:

• Formulations and Finished Medicines: Cipla offers 1,500+ products across 65 therapies and 50 dosage forms. It leads in respiratory and urology, with a strong presence in cardiology and HIV treatments.
• APIs: It manufactures and supplies APIs for its own medicines and for global generic partners, ensuring strong supply chain control.
• Global Markets: India, North America and South Africa are major revenue drivers, supported by subsidiaries and market partnerships.
• Research & Innovation: Its R&D teams focus on complex generics, respiratory delivery systems, biosimilars and new technologies.
• Consumer & OTC: Cipla also builds wellness and OTC products, boosted by acquisitions in key markets like South Africa.

These activities collectively serve retail consumers, hospital systems, global healthcare institutions and pharmaceutical partners, even though Cipla itself is not a financial services provider.

ESG & Sustainability Focus

As of March 2025, Cipla’s India Manufacturing Operations report the following sustainability achievements:

• Renewable Electricity Share: 64%
• Water Positive: 1.75 times
• GHG Emissions Reduced by 58% compared to the FY 2019–20 baseline
• Certified Zero Waste to Landfill

Leadership Team

Cipla Ltd Share Price History

[Dynamic Table to be Included]

Top Mutual Funds Invested in Cipla Ltd Share (As on 31st October 2025)